The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hemostats market reached a value of US$ 3.13 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hemostats are used to compress blood vessels and prevent the flow of blood or other fluids. They are generally used in adjunct to surgical procedures to manage bleeding. Hemostatic agents offer various benefits, including decreased wound healing and operative time, better management of anticoagulated patients, and reduction in the patient recovery period. A wide range of surgical hemostatic agents is available in the market that vary widely in their composition, cost, immunogenicity, mechanism of action, application and adherence.
On account of the significant rise in the prevalence of chronic disorders, cesarean deliveries, fatal injuries and major organ surgeries, there has been an increasing demand for hemostats. These agents help prevent blood loss during surgical procedures, particularly for nonanatomic and sensitive structures, and among patients with hemostatic abnormalities. Besides this, their use helps in lowering the cost of the procedure, which has led to their rapid adoption among healthcare providers. Moreover, with technological advancements, leading manufacturers have developed absorbable adjunctive hemostats that help professionals to control disruptive bleeding more efficiently as compared to traditional methods. Additionally, they are utilizing nano- and micro-materials for treating uncontrolled hemorrhage and internal bleeding. Market players have also introduced advanced laparoscopic hemostats designed to enhance the quality of surgical operations and allow for less invasive procedures. Along with these developments, improvements in healthcare facilities and extensive research and development (R&D) activities to launch new products, are providing a positive impact on the industry.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemostats market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and formulation.
Breakup by Product:
Breakup by Application:
Breakup by Formulation:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Arch Therapeutics Inc., Baxter International Inc., B. Braun Melsungen Aktiengesell, C. R. Bard Inc., GELITA MEDICAL GmbH, Integra LifeSciences Corporation, Johnson & Johnson, Pfizer Inc., Stryker Corporation, Teleflex Incorporated and Z-Medica LLC.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, Formulation, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Arch Therapeutics Inc., Baxter International Inc., B. Braun Melsungen Aktiengesell, C. R. Bard Inc., GELITA MEDICAL GmbH, Integra LifeSciences Corporation, Johnson & Johnson, Pfizer Inc., Stryker Corporation, Teleflex Incorporated and Z-Medica LLC.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at